You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials in progress
373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2

 

Online download statistics by month:

Online download statistics by month: November 2020 to August 2025

AbstractFullPdf
Nov 2020238022
Dec 202052010
Jan 20216009
Feb 202126012
Mar 202162014
Apr 202174013
May 202123019
Jun 20210015
Jul 20210011
Aug 2021009
Sep 2021009
Oct 202144032
Nov 202164018
Dec 20214007
Jan 20221608
Feb 20226209
Mar 202246010
Apr 20226806
May 202248013
Jun 202264011
Jul 20224604
Aug 20223409
Sep 20222005
Oct 20221604
Nov 202236011
Dec 20221405
Jan 20231606
Feb 20234208
Mar 20232805
Apr 20233205
May 20234807
Jun 20239807
Jul 2023140010
Aug 20239204
Sep 20237806
Oct 20236604
Nov 20237409
Dec 20235605
Jan 20244401
Feb 20244202
Mar 20247706
Apr 20245605
May 202438010
Jun 20243205
Jul 20243801
Aug 20243004
Sep 20244206
Oct 202476011
Nov 20245002
Dec 20246006
Jan 202534010
Feb 20252002
Mar 20250013
Apr 2025007
May 2025005
Jun 2025106
Aug 2025100
Total25640473